



Critical Illness Neuropathy

JILL McEWEN, MD FRCPC

*Clinical Professor & Director
Undergraduate Education Program
Department of Emergency Medicine
University of British Columbia
Vancouver, BC Canada
Immediate Past President
Canadian Association of Emergency Physicians*






Vancouver Canada




University of British Columbia, Vancouver BC




Disclosure

- No conflict of interest to declare



Critical Illness Neuropathy Objectives

- Discuss current relevance
- Discuss the spectrum of disorders
- Discuss diagnosis
- Implement preventive measures
- Be aware of the state of current evidence



History



- Osler (1892)
“Rapid loss of flesh” in sepsis
- Bolton et al (1984)
 - ✓ CIN & CIM
- Maher et al (1995)
 - ✓ Common cause of failure to wean from ventilator

Relevance of Critical Illness Neuropathy

- Common in ICU Patients
 - 21-74% of critically ill patients
- Increased Morbidity Mortality
 - Short term (in ICU & hospital) &
 - Long term (after discharge)
- Decreased Quality of Living
- Costly
 - Leads to prolonged ICU stay, prolonged hospitalization
 - Prolonged and incomplete post-ICU rehabilitation



Prevalence

- Estimates only, due to variability in
 - ✓ Diagnostic criteria
 - ✓ Patient populations studied
- Adults in ICU > 2 weeks
 - ✓ mechanical ventilation & sepsis or multi-organ failure:
 - 43-49%*

* Stevens RD et al. (2007). *Neuromuscular dysfunction acquired in critical illness: a systematic review*. Intens Care Med. 33: 1876-91.


• A review paper 21-74% of ICU patients**

** Farhan H et al. (2015). *Acquired muscle weakness in the surgical intensive care unit: Nosology, epidemiology, diagnosis and prevention*. Anaesthesiology 124:1, 207-34.




Definitions

- **Critical Illness Polyneuropathy (CIP)**
 - ✓ Limb & respiratory weakness
 - ✓ Failure to wean off mechanical ventilation
- **Critical Illness Myopathy (CIM)**
 - ✓ Primary myopathy (proximal > distal)
 - ✓ Sensory preservation, atrophy
- **Critical Illness Polymyoneuropathy (CIPMN) or CI Neuromyopathy (CINM)**
 - ✓ Combination weakness & sensory loss
 - ✓ Distal > proximal
- **Intensive Care Unit Acquired Weakness (ICUAW)**




CI Myopathy – Proximal > distal
 CI Polyneuropathy – Distal > proximal



CIP (Polyneuropathy)

- Diffuse sensory & motor axonal neuropathy
- 50% of patients with severe sepsis & septic shock
- Onset variable 2 days – several weeks after onset of septic shock



CIM (Myopathy)

- Diffuse inflammatory myopathy that involves muscles of limb and trunk
- Associated with severe sepsis & septic shock
- Also associated with prolonged periods of drug-induced neuromuscular paralysis, particularly if combined with
 - ✓ high dose corticosteroid therapy
 - ✓ status asthmaticus treated with high dose steroids





Figure 1. Classification of intensive care unit-acquired weakness (*ICUAW*). *CIP*, critical illness polyneuropathy; *CINM*, critical illness neuromyopathy; *CIM*, critical illness myopathy.

From: Stevens DR et al. (2009). *A framework for diagnosing and classifying intensive care unit-acquired weakness*. Crit Care Med, 37:10, S299-308.




Clinical Features

- Often undetected until there is an unexplained failure to wean off mechanical ventilation
- Physical exam: flaccid paralysis with hypo- or a-reflexia



What can be done?



From NEJM Critical Care Challenge: ICU-acquired weakness and recovery from critical illness.
[doi/story/10.1056/feature.2014.04.15.26](https://doi.org/10.1056/feature.2014.04.15.26)


Diagnosis


✓ CIP

- nerve conduction studies: slowed conduction in sensory & motor fibres

✓ CIM

- electromyography: myopathic changes
- muscle biopsy: atrophy, loss of myosin fibrils & inflammatory infiltration





Differential Diagnosis of Neuromuscular Weakness

Includes:

- Guillain – Barre syndrome
- Rhabdomyolysis
- Cachexic myopathy
- CIN and CIM

Differential Diagnosis

Table 1. Neuromuscular Differential Diagnosis of “Failure to Wean From Ventilator”.

Motor neuron	Amyotrophic lateral sclerosis
	Poliomyelitis
	Guillain-Barre syndrome
	Critical illness polyneuropathy
	Critical illness polyneuropathy/myopathy
	Heavy metal toxicity
	Vasculitis
	Sarcoidosis
	Mononeuritis multiplex
Neuromuscular junction	Myasthenia gravis
	Neuromuscular blockade
	Lambert-Eaton myasthenic syndrome
	Botulinum toxicity
	Organophosphate toxicity
Muscle	Tetrodotoxin toxicity
	Rhabdomyolysis
	Mitochondrial myopathy
	Muscular dystrophy (eg, Myotonic dystrophy)
	Critical illness myopathy
	Acid maltase deficiency

Diagnostic Criteria

Table 2. Suggested Diagnostic Criteria for Critical Illness Polyneuropathy and Critical Illness Myopathy.^a

CIP	CIM
Critically ill (sepsis and multi-organ failure)	Not required; typically exposed to variable combination of neuromuscular blocking agent and corticosteroids in the setting of sepsis and multi-organ failure
Limb weakness is present	Limb weakness is present
Difficulty in weaning from mechanical ventilatory support with the exclusion of cardiac and pulmonary causes	Difficulty in weaning from mechanical ventilatory support with the exclusion of cardiac and pulmonary causes
Electrophysiological evidence of <ol style="list-style-type: none"> I. Axonal sensorimotor neuropathy 	Electrophysiological evidence of <ol style="list-style-type: none"> 1. Preserved sensory response (>80% of lower limit of normal) 2. Reduced motor responses (compound muscle action potential <80% lower limit of normal) 3. Normal repetitive nerve simulation, and EMG with short-duration, low-amplitude motor unit potential with early full or normal recruitment of motor unit action potentials 4. Muscle inexcitability with direct muscle stimulation
Other causes of acute neuropathy should be excluded, for example, porphyria, acute massive intoxications of heavy metals, and vasculitis	Muscle biopsy consistent with myopathy and myosin loss


Adapted from Bolton CF. (2005). *Neuromuscular manifestations of critical illness*. Muscle Nerve: 32:140-63..

Latronico N, & Bolton CF. (2011). *Critical Illness polyneuropathy & myopathy: a major cause of muscle weakness and paralysis*.

Lancet Neurol: 10:931-41.


Pathophysiology

- Unclear
- Involves pathology in the following mechanisms:
 - ✓ Electrical
 - ✓ Microvascular
 - ✓ Metabolic
 - ✓ Bioenergetic



Representation of potential mechanisms reducing the force-generating potential of skeletal muscle in intensive care unit-acquired weakness.

- 1: neuropathy; 2: altered myocyte structure and myofilament integrity; 3: sarcoplasmic reticulum (SR) dysfunction; 4: electrical inexcitability
5: bioenergetic failure**



Critical Illness

Cytokines Produced

```
graph TD; A["Critical Illness<br/>Cytokines Produced"] --> B["Microvascular<br/>Changes"]; A --> C["Metabolic<br/>Changes"]; A --> D["Electrical<br/>Changes"]; B --> B1["Vasodilation"]; B --> B2["↑ Permeability"]; B --> B3["Leukocytes<br/>extravasion"]; B --> B4["Hypoxemia"]; C --> C1["Hyperglycemia"]; C --> C2["↑ Catabolism"]; C --> C3["Mitochondrial<br/>dysfunction"]; C --> C4["ROS production"]; C --> C5["↓ Albumin"]; D --> D1["Na+ Channel<br/>dysfunction"]; D --> D2["Ca2+ Homeo-<br/>stasis dysf'n"]; D --> D3["Cells become<br/>inexcitable"];
```

Microvascular Changes

Vasodilation
↑ Permeability
Leukocytes
extravasion
Hypoxemia

Metabolic Changes

Hyperglycemia
↑ Catabolism
Mitochondrial
dysfunction
ROS production
↓ Albumin

Electrical Changes

Na⁺ Channel
dysfunction
Ca²⁺ Homeo-
stasis dysf'n
Cells become
inexcitable

← Critical Illness Polyneuropathy/Myopathy →




Impact

Depends on population

- If mild – can recover in weeks
- Full recovery in 50%
- 10% last > 1 year
- Some have long-term paresis





Consequences

- Prolonged need for mechanical ventilation
- Longer ICU stay
- Longer hospital stay
- Slower rehabilitation
- Some may develop contractures





Treatment?

1. Prevent Risk Factors whenever possible

- ✓ Try to decrease ICU time
- ✓ Wean off ventilator quickly
- ✓ Aggressively treat sepsis, ARDS
- ✓ Avoid hyperglycemia

2. Physical & Rehabilitation Therapy

- ✓ There are guidelines, however there is limited high quality evidence

A..B..C..D..E..**F..G...**For Post-ICU QOL



**Awake and Breathing
Coordination**



**Choose light
sedation
& avoid benzos**



**Delirium
Monitoring
& Management**



**Early
Mobility
& Exercise**



**Feeding &
Early Adequate
Protein**



**Gain
Function
& Grow Muscle**




Physical rehabilitation for critical illness myopathy and neuropathy: an abridged version of Cochrane Systematic Review

J. MEHRHOLZ ^{1, 2}, M. POHL ³, J. KUGLER ², J. BURRIDGE ⁴, S. MÜCKEL ¹, B. ELSNER ²

A systematic review:

- Does physical rehabilitation improve activities of daily living in patients with CIP & CIM?
- 3587 references >>..... 24.....0 RCTs
 - 22 didn't meet diagnostic criteria & 2 not RCTs



Problems in rehab literature

- Populations variable
 - ✓ No defined CIP or CIM criteria
- Interventions
 - ✓ Cycling
 - ✓ Sit-to-stand training
 - ✓ Walking & gait training
 - ✓ Neuromuscular electrical vs usual therapy
 - ✓ Muscle strength training

Prevention of ICU-acquired muscle weakness

Early sepsis treatment	Treat muscle inactivity	Treat excessive muscular load	Metabolic derangement	Potential pharmacological intervention*
Early diagnosis (cultures)	Early goal-directed mobilization in ICU (SOMS)	Lung-protective mechanical ventilation	Early enteral nutrition	Vitamin D supplementation
Early focused antibiotic treatment	Early muscle stimulation	Goal-oriented mobilization	Late parenteral nutrition	ACE-inhibitors
Consider surgical drainage of focus	Spontaneous breathing trials	Adequate pain management	Glycemic control 110 – 180 mg/dl	PGC-1a inducers
Fluid resuscitation	Daily review of lines and tubes that may hinder mobilization	Avoid aggressive mobilization in patients with inadequate tissue oxygenation	Electrolyte correction	Melanocortin-4 receptor antagonists
	Avoid drug side effects <ul style="list-style-type: none"> • Daily drug review (NMBAs, opioids, corticosteroids) • Drug holidays 			Myostatin inhibitors
				Complete reversal of neuromuscular blockade
				Melatonin and oxytocin

* Promising concept, not yet in place. Currently under study.

UNDER STUDY

Recommendations for Prevention of ICU-Acquired Weakness p.1

Table 2. Recommendations for Prevention of ICU-acquired Muscle Weakness

	Study Design/ Sample Size	Setting	Intervention	Muscle Weakness	ICU LOS	Hospital LOS	Mechanical Ventilation (Duration or Weaning)	Mortality	Level*	Grade†
Aggressive treatment of sepsis										
Ranieri <i>et al.</i> ²⁰⁰	RCT/44 patients (37 completed)	Medical and surgical ICU	Protective (low tidal) mechanical ventilation vs. conventional	N/R	N/R	N/R	↓ (8 d less)‡	↓ (38 vs. 58%)	B	IIA
Rivers <i>et al.</i> ²⁰¹	RCT/263 patients	Mostly medical patients, but also surgical	6 h of early goal-directed therapy vs. standard therapy	N/R	N/R	No difference	No difference	↓ (30.5 vs. 46.5%)‡	B	
Eisner <i>et al.</i> ²⁰²	RCT/902 patients	Medical and surgical patients	Protective (low tidal) mechanical ventilation vs. Conventional	N/R	N/R	N/R	Proportion of patients achieving unas- sisted breathing by day 28 (62 vs. 52%)‡	↓ (31 vs. 40%)‡	B	
Trzeciak <i>et al.</i> ²⁰³	Historical control trial/38 patients	Medical patients sent to ICU directly from ER	Early goal-directed therapy vs. standard therapy	N/R	↓ (1.8 vs. 4.2 d)	↓ (9 vs. 13 d)	N/R	↓ (18.2 vs. 43.8%)	B	
Yealy <i>et al.</i> ¹³⁴	RCT/1341 patients	Mostly medical patients	Protocol-based early goal-directed therapy vs. protocol-based standard therapy vs. usual care	N/R	No difference	No difference	No difference	No difference	B	
ARISE Investigators; ANZICS Clinical Trials Group ²⁰⁴	RCT/1600 patients	Medical patients sent to ICU directly from ER	Early goal-directed therapy vs. usual care	N/R	No difference	No difference	No difference	No difference	B	
Optimize the muscular load: early (< 48 h) mobilization										
Kangas <i>et al.</i> ²⁰⁵	RCT/50 patients	Surgical patients	Early movement of the ankle in a brace vs. Achilles tendon immobilization in tension using a below- knee cast with the ankle in a neutral position for 6 wk	Excellent to good isokinetic calf scores in the early movement group (56 vs. 29%)	N/R	N/R	N/R	N/R	B	IIA
Schweickert <i>et al.</i> ³⁹	Prospective RCT/104	Medical ICU	Progressive physical and occupational therapy vs. standard physical therapy	↓ (35 vs. 49%)	↓ (5.9 vs. 7.9 days)	No difference	↓ (3.4 vs. 6.1 days)‡	↓ (18 vs. 25 %)	B	
Burtin <i>et al.</i> ²⁰⁶	Prospective RCT/90	Medical and surgical ICU	Standard PT mobilization plus cycling exercise	Improved quadriceps force at hospital discharge‡	No difference	↓ (36 vs. 40 d)	No difference	↓ (8 vs. 10%)	B	
Routsi <i>et al.</i> ⁴²	RCT/140 patients	Medical and surgical ICU	Electrical muscle stimulation to prevent CIPNM	MRC score improved (58 vs. 52)‡	↓ (14 vs. 22 d)	N/R	↓ (1 vs. 3 d)‡	No difference	B	
Keep the respiratory muscles moving										
Spontaneous breaths during mechanical ventilation										
Rathgeber <i>et al.</i> ²⁰⁷	Prospective controlled trial/596 patients	Surgical ICU	Biphasic positive airway pressure ventilation vs. synchronized intermittent mandatory ventilation vs. assist/controlled mandatory ventilation	N/R	N/R	N/R	↓ (10.1 vs. 14.7 vs. 13.2 h)‡	N/R	B	IIA

Farhan H et al. (2015). *Acquired muscle weakness in the surgical intensive care unit: Nosology, epidemiology, diagnosis and prevention.* Anaesthesiology 124:1, 207-34.

	Study Design/ Sample Size	Setting	Intervention	Muscle Weakness	ICU LOS	Hospital LOS	Mechanical Ventilation (Duration or Weaning)	Mortality	Level* Grade†
Putensen <i>et al.</i> ²⁰⁸	RCT/30 patients	Trauma ICU	Airway pressure release ventilation with spontaneous breathing vs. pressure support controlled ventilation	N/R	↓ (23 vs. 30 d)‡	N/R	↓ (15 vs. 21 d)‡	No difference	B
Protective mechanical ventilation									
Amato <i>et al.</i> ²⁰⁹	RCT/53 patients	Medical and surgical ICU	Protective (low tidal) mechanical ventilation vs. conventional	N/R	N/R	N/R	Early weaning (66 vs. 29%)‡	↓ (38 vs. 71 %)‡	B I
ARDS Network ²¹⁰	RCT/861 patients	Medical and surgical ICU	Protective (low tidal) mechanical ventilation vs. conventional	N/R	N/R	N/R	↓ (2 d less)‡	↓ (31 vs. 39.8%)‡	B
Maxwell <i>et al.</i> ²¹¹	RCT/63 patients	Surgical or trauma ICU	Low tidal volume ventilation vs. APRV	N/R	↓ (14.18 vs. 16.47 d)	N/R	↓ (8 vs. 10.49 d)	No difference	B
Holiday periods									
Kress <i>et al.</i> ²¹²	RCT/128 patients	Medical ICU	Daily interruption vs. standard interruption of sedative drug infusion	N/R	↓ (3.5 d less)‡	↓ (13.3 vs. 16.9 d)	↓ (4.9 vs. 7.3 d)‡	↓ (36 vs. 46.7%)	B I
Girard <i>et al.</i> ⁶⁶	RCT/336 patients	Medical ICU	Daily spontaneous awakening trial followed by a spontaneous breathing trial vs. sedation per usual care plus a daily spontaneous breathing trial	N/R	↓ (9.1 vs. 12.9 d)‡	↓ (14.9 vs. 19.2 d)‡	Ventilator-free days within 28-d study period: ↑ (14.7 vs. 11.6 d; mean increase 3.1 d)‡	↓ (44 vs. 58%)‡	B
Robinson <i>et al.</i> ²¹³	RCT/143 patients	Surgical ICU	Daily interruption vs. standard interruption	N/R	↓ (4.1 vs. 5.9 d)	↓ (12 vs. 18 d)‡	↓ (1.2 vs. 3.2 d)‡	↓ (14.7 vs. 17.6%)	B
Papazian <i>et al.</i> ⁴¹	RCT/340 patients	Medical and surgical ICU	Short period of cisatracurium besylate vs. placebo	No difference	N/R	Days outside the ICU: ↑ (47.7 vs. 33.5 d)‡	Ventilator free days (at 90 d): ↑ (10.6 vs. 8.5 d)‡	At 90 d: ↓ (30.8 vs. 44.6%)‡	B
Mehta <i>et al.</i> ²¹⁴	RCT/430 patients	Medical and surgical ICU	Protocolized sedation plus daily sedation interruption vs. protocolized sedation	N/R	No difference	No difference	In surgical and trauma patients: ↓ (6 vs. 13 d)‡	N/R	B
Optimal nutrition									
Enteral nutrition									
Singh <i>et al.</i> ²¹⁵	RCT/43 patients	Surgical ICU	Feeding jejunostomy from 12 h postoperatively vs. control	N/R	N/R	No difference	N/R	No difference	B IIB
Marik and Zaloga ²¹⁶	Systematic review/15 RCT	Surgical or trauma ICU	Early vs. delayed enteral nutrition	N/R	N/R	↓ (2.2 d less; in trauma/head injury/burn patients 4.04 d less)‡	N/R	↓ (8 vs. 11.5%)	B
Minard <i>et al.</i> ²¹⁷	RCT/30 patients	Trauma ICU	Early vs. delayed enteral feedings	N/R	No difference	No difference	No difference	↓ (8 vs. 27%)‡	B

	Study Design/ Sample Size	Setting	Intervention	Muscle Weakness	ICU LOS	Hospital LOS	Mechanical Ventilation (Duration or Weaning)	Mortality	Level*	Grade†
Lewis <i>et al.</i> ²¹⁸	Systematic review and metanalysis/ 837 patients	Surgical patients	Enteral feeding started within 24 h after surgery vs. nil by mouth management in elective gastrointestinal surgery	N/R	N/R	↓ (10.4 vs. 12.9 d)‡	N/R	↓ (7 vs. 13%)	A	
Braunschweig <i>et al.</i> ²¹⁹	Metanalysis/ 27 studies; 1,828 patients	Medical and surgical patients	Parenteral nutrition vs. tube feeding vs. standard care	N/R	N/R	N/R	N/R	↑ In standard of care	A	
Heyland <i>et al.</i> ²²⁰	Systematic review/8 RCT	Medical and surgical ICU	Early vs. delayed enteral nutrition or intravenous fluids	N/R	No difference	No difference	N/R	↓ (6.3 vs. 14.6%)	B	
Dvorak <i>et al.</i> ²²¹	RCT/23 patients (17 patients included in analysis)	Trauma ICU	Early vs. late enteral feeding	N/R	N/R	↑ (53 vs. 37.9 d)	↑ (763 vs. 502 h)	N/R	B	
Peck <i>et al.</i> ²²²	RCT/95 patients eligible (data analyzed from 27 patients)	Trauma (burn) ICU	Early vs. late enteral feeding on postburn metabolism	N/R	↑ (40 vs. 37 d)	No difference	↑ (32 vs. 23 d)	↓ (28 vs. 38%)	B	
Artinian <i>et al.</i> ²²³	Retrospective cohort/4049 patients	Medical ICU	Early vs. delayed enteral nutrition	N/R	↑ (10.9 vs. 10.2 d)‡	N/R	No difference	↓ (28.7 vs. 33.5%)‡	C	
Harvey <i>et al.</i> ²²⁴	RCT/2400 patients	Medical and surgical ICU	Parenteral vs. enteral nutrition	N/R	No difference	No difference	No difference	↓ (33.1 vs. 34.2%)	B	
Parenteral nutrition Casaer <i>et al.</i> ¹⁶²	RCT/4640 patients	ICU	Late vs. early parenteral nutrition	N/R	↓ (3 vs. 4 d)‡	↓ (14 vs. 16 d)‡	Requiring > 2 d of mechanical ven- tilation: ↓ (36.3 vs. 40.2%)‡	No difference	B	IIB
Hermans <i>et al.</i> ¹³¹	RCT/600 patients	Mostly surgical but also medical ICU	Late vs. early parenteral nutrition	↓ (34 vs. 43 %)‡	↓ (11 vs. 13 d)‡	↓ (27 vs. 32 d)	↓ (6 vs. 7 d)	↑ (11 vs. 9%)	B	
Heidegger <i>et al.</i> ¹⁶⁴	RCT/305 patients	Surgical and medical ICU	Supplemental parenteral nutrition with enteral nutrition vs. enteral nutri- tion alone from day 4 to 8 in the ICU	N/R	No difference	No difference	No difference	↓ (13 vs. 18%)	B	
Doig <i>et al.</i> ²²⁵	RCT/1,372 patients	Surgical and medical ICU	Early parenteral nutrition within 24 h after ICU admission vs. standard therapy	N/R	↓ (8.6 vs. 9.3 d)	No difference	↓ (7.26 vs. 7.73 d per 10 patient × ICU days)‡	↓ (21.5 vs. 22.8%)	B	
Tight glycemic control van den Berghe <i>et al.</i> ¹⁹³	RCT/1548 patients (preplanned subanalysis of patients still in ICU on day 7: 405 patients)	Surgical ICU	Intensive insulin therapy vs. conventional management	↓ (25 vs. 49%)‡	↓ (14 vs. 15 d)‡	N/R	↓ (11 vs. 13 d)‡	↓ (12 vs. 21%)‡	B	III

	Study Design/ Sample Size	Setting	Intervention	Muscle Weakness	ICU LOS	Hospital LOS	Mechanical Ventilation (Duration or Weaning)	Mortality	Level* Grade†
Brunkhorst <i>et al.</i> ²²⁶	RCT/537	Medical and surgical ICU	Intensive insulin therapy vs. conventional management	N/R	↑ (16 vs. 14 d)	N/R	No difference	↑ (39.7 vs. 35.4%)	B
Wiener <i>et al.</i> ²²⁷	Meta-analysis/ 34 trials; 29 RCTs contributed data	Medical and surgical ICU	Intensive insulin therapy vs. conventional management	N/R	N/R	N/R	N/R	↓ (21.6 vs. 23.3%)	A
Griesdale <i>et al.</i> ²²⁸	Meta-analysis/26 trials	6 trials in medical ICU	Intensive insulin therapy vs. conventional management	N/R	N/R	N/R	N/R	↓ in the surgical ICU, ‡not in the others	A
Finfer <i>et al.</i> ²²⁹	RCT/6104 patients	Medical and surgical ICU	Intensive insulin therapy vs. conventional management	N/R	No difference	No difference	No difference	↑ (27.5 vs. 24.9%)‡	B
Preiser <i>et al.</i> ²³⁰	RCT/1101	Medical and surgical ICU	Intensive insulin therapy vs. conventional management	N/R	No difference	No difference	No difference	↑ (17.2 vs. 15.3%)	B
Marik and Preiser ²³¹	Systematic review + meta-analysis/7 trials	Medical and surgical ICU	Impact of tight glycemic control	N/R	N/R	N/R	N/R	No difference	A
Kansagara <i>et al.</i> ²³²	Systematic review/21 trials	Medical and surgical ICU	Benefits and harms of IIT in hospitalized patients	N/R	↓ (1.484 d less) in the surgi- cal ICU	No difference	N/R	No difference	A
Hermans <i>et al.</i> ⁴³	Systematic review/2 trials	Medical and surgical ICU	IIT on incidence of CIM/CIP	↓‡	↓ (1.48 d less)‡	N/R	↓ (2 d less)‡	No difference	A

* American Heart Association levels of evidence: A (multiple populations evaluated, data derived from multiple randomized clinical trials or meta-analyses), B (limited populations evaluated, data derived from a single randomized clinical trial or nonrandomized studies), and C (very limited populations evaluated, only consensus opinion of experts, case studies, or standard of care). † Recommendation: I (benefits greatly surpass risks, procedure/treatment should be performed or administered), IIA (benefits surpass risks, additional focused studies needed, it is reasonable to perform procedure/treatment), IIB (benefit surpasses risks, additional studies with broad objectives needed, procedure/treatment may be considered), and III (risks surpasses benefit, procedure/treatment should not be performed). ‡ Statistically significant.

APRV = airway pressure release ventilation; ARDS = acute respiratory distress syndrome; ARISE = Australasian Resuscitation in Sepsis Evaluation; CIM = critical illness myopathy; CIP = critical illness polyneuropathy; CIPNM = critical illness polyneuropathy and myopathy; ER = emergency room; ICU = intensive care unit; IIT = intensive insulin therapy; LOS = length of stay; MRC = Medical Research Council Scale for muscle strength; N/R = not reported; PT = physical therapy; RCT = randomized controlled trial.

Summary of Interventions

- Aggressive treatment of underlying problem
- Minimize paralytic agents, sedation & duration of mechanical ventilation
- Institute early active & passive mobilization even during mechanical ventilation
- Optimize nutrition
 - enteral early, parenteral later
- Target glycemic levels 110-180 mg/dl (140 target)
 - not “tight” 80-110mg/dl





Thank you!